Cipla Limited
Cipla Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹7,404 cr of revenue in its latest quarter (Q2 FY27) and kept 11.9% of sales as profit. It is the 7th largest of 9 Pharmaceuticals companies we track, by market value.
| Segment | FY24 | FY25 | Share |
|---|---|---|---|
| Pharmaceuticals | 24,842 | 26,446 | 96% → 95% |
| New ventures | 1,112 | 1,303 | 4% → 5% |
| Total | 25,954 | 27,750 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
Healthier than 65% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 16–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 64
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in CIPLA?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 0%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-03.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹7,404 cr |
| Other Income | ₹151 cr |
| Total Income | ₹7,555 cr |
| Cost of Materials | ₹1,524 cr |
| Purchases of Stock-in-Trade | ₹1,313 cr |
| Inventory Change (±) | ₹-203 cr |
| Employee Benefit Expense | ₹1,475 cr |
| Finance Costs | ₹17 cr |
| Depreciation & Amortisation | ₹345 cr |
| Other Expenses | ₹1,908 cr |
| Total Expenses | ₹6,378 cr |
| Profit before Tax | ₹1,177 cr |
| Tax Expense | ₹321 cr |
| Share of JV / Associates | ₹-5 cr |
| Net Profit | ₹852 cr |
| Net margin on total income | 11.3% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 6,541 cr | 7,119 cr | 7,404 cr |
| Total income | 6,689 cr | 7,330 cr | 7,555 cr |
| Expenses | 5,982 cr | 6,248 cr | 6,378 cr |
| Profit before tax | 707 cr | 1,082 cr | 1,177 cr |
| Tax | 157 cr | 295 cr | 321 cr |
| Net profit (owners' share) | 555 cr | 789 cr | 878 cr |
| Net margin (owners' share, on revenue) | 8.5% | 11.1% | 11.9% |
| EPS (₹) | 6.87 | 9.77 | 10.86 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limited | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Dr. Reddy's Laboratories Limited | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limitedthis company | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Aurobindo Pharma Limited | ₹1,695 | ₹97,502 cr | 23.7 | 10.9% | 11.3% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹13 / share | 5 Jun 2026 |
| Dividend | ₹13 / share | 27 Jun 2025 |
| Dividend | ₹3 / share | 27 Jun 2025 |
| Dividend | ₹13 / share | 2 Aug 2024 |
| Dividend | ₹8.5 / share | 21 Jul 2023 |
| Dividend | ₹5 / share | 8 Aug 2022 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.